Core Insights - HNI Corporation reported a strong fiscal 2025 with significant growth in both net sales and operating margins, achieving a 6% year-over-year increase in organic net sales and a 100 basis point expansion in non-GAAP operating profit margin to 10.5% [1][4] Financial Performance - The legacy Workplace Furnishings segment saw a full-year non-GAAP diluted EPS of $3.74, representing a 22% increase from 2024, with total net sales rising 12% and organic sales up 6% [3][6] - The company achieved an adjusted operating margin of 9.4%, an 80 basis point increase, driven by volume growth, productivity gains, and synergies from Kimball International [3][6] Strategic Initiatives - HNI's management highlighted a profitability improvement initiative that began three years ago, which has expanded operating margins by nearly 1,000 basis points [2] - The acquisition of Steelcase, completed on December 10, is expected to generate $120 million in synergies and long-term accretion of $1.20, with integration efforts already underway [6][8] Market Outlook - For fiscal 2026, HNI anticipates a fifth consecutive year of double-digit non-GAAP EPS growth, although it expects a softer first quarter with total net sales projected to rise "more than 130%" due to the Steelcase acquisition [5][12] - The company remains optimistic about Workplace Furnishings demand, citing a return to office trends and positive indicators in the office leasing market [14] Operational Developments - HNI's management noted that the Steelcase acquisition would not alter dealer partnerships or brand distribution, ensuring continuity for customers and dealers [8] - The company plans to optimize its network and expects initiatives to contribute an incremental $0.25 to $0.30 of EPS over the next three years [13]

Group 1 - Cardinal Health Inc. reported third-quarter 2025 adjusted EPS of $2.35, a 13% increase year over year, surpassing the consensus estimate of $2.17 [1] - Sales remained flat at $54.9 billion, missing the consensus of $55.35 billion, while adjusted operating earnings increased by 21% to $807 million [1] - The Pharmaceutical and Specialty Solutions segment's sales were unchanged at $50.6 billion [1] Group 2 - Revenue for the Global Medical Products and Distribution (GMPD) segment rose by 2% to $3.2 billion, driven by volume growth from existing customers [2] - Segment profit increased by 14% to $662 million in the third quarter, supported by brand and specialty products, MSO platforms, and positive generics program performance [6] - The company raised its fiscal year 2025 adjusted EPS guidance from $7.85-$8.00 to $8.05-$8.15, compared to the consensus of $7.96 [3] Group 3 - Cardinal Health anticipates double-digit non-GAAP EPS growth in fiscal 2026 despite evolving macroeconomic conditions [4] - The outlook for the Pharmaceutical and Specialty Solutions segment profit was increased to 11.5% to 12.5% growth, up from a previous range of 10% to 12% [6] - The company expects GMPD segment profit to be consistent with fiscal 2025 segment profit amid macro uncertainty [6] Group 4 - CAH stock is trading 2.30% higher at $144.53 [5] - The company plans to discuss its fiscal 2026 and beyond expectations at its upcoming Investor Day on June 12 [6]